Biomarin: Interest in new dwarfism drug for children exceeds expectations
Following European approval, interest in Biomarin's treatment for children with achondroplasia, Voxzogo, beats company expectations, it reports. US approval could be coming next month.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Ascendis might gain strong competition in the shape of Biomarin's new treatment for achondroplasia, also known as dwarfism.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin gets ready for launch in second half-year of 2021
For subscribers
Ascendis aiming to become market leader
For subscribers
